Organon & Co. Net Income
Organon & Co. (OGN) reported Net Income of $108.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-07-31
- Organon & Co. net income (loss) attributable to parent for the quarter ending 2026-06-30 was $108.00M, a 25.52% decline year-over-year.
- Organon & Co. net income (loss) attributable to parent for the quarter ending 2026-03-31 was $146.00M, a 67.82% increase year-over-year.
- Organon & Co. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$205.00M, a 288.07% decline year-over-year.
- Organon & Co. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $160.00M, a 55.43% decline year-over-year.
- Organon & Co. net income (loss) attributable to parent for fiscal 2020 was $2.16B, a 32.88% decline from fiscal 2019.
- Organon & Co. net income (loss) attributable to parent for fiscal 2019 was $3.22B.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $108.00M 10-Q · filed 2026-07-31 | $254.00M 10-Q · filed 2026-07-31 | $49.00M derived: sum of 3 quarters · filed 2026-07-31 | $209.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $146.00M 10-Q · filed 2026-05-04 | -$59.00M derived: sum of 2 quarters · filed 2026-05-04 | $101.00M derived: sum of 3 quarters · filed 2026-05-04 | $246.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | -$205.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | -$45.00M derived: sum of 2 quarters · filed 2026-04-24 | $100.00M derived: sum of 3 quarters · filed 2026-07-31 | $187.00M DEF 14A · filed 2026-04-24 |
| 2025-09-30 | $160.00M 10-Q · filed 2025-11-10 | $305.00M derived: sum of 2 quarters · filed 2026-07-31 | $392.00M 10-Q · filed 2025-11-10 | $501.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $145.00M 10-Q · filed 2026-07-31 | $232.00M 10-Q · filed 2026-07-31 | $341.00M derived: sum of 3 quarters · filed 2026-07-31 | $700.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $87.00M 10-Q · filed 2026-05-04 | $196.00M derived: sum of 2 quarters · filed 2026-05-04 | $555.00M derived: sum of 3 quarters · filed 2026-05-04 | $750.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $109.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | $468.00M derived: sum of 2 quarters · filed 2026-04-24 | $663.00M derived: sum of 3 quarters · filed 2026-04-24 | $864.00M DEF 14A · filed 2026-04-24 |
| 2024-09-30 | $359.00M 10-Q · filed 2025-11-10 | $554.00M derived: sum of 2 quarters · filed 2025-11-10 | $755.00M 10-Q · filed 2025-11-10 | $1.30B derived: sum of 4 quarters · filed 2026-04-24 |
| 2024-06-30 | $195.00M 10-Q · filed 2025-08-06 | $396.00M 10-Q · filed 2025-08-06 | $942.00M derived: sum of 3 quarters · filed 2026-04-24 | $1.00B derived: sum of 4 quarters · filed 2026-04-24 |
| 2024-03-31 | $201.00M 10-Q · filed 2025-05-02 | $747.00M derived: sum of 2 quarters · filed 2026-04-24 | $805.00M derived: sum of 3 quarters · filed 2026-04-24 | $1.05B derived: sum of 4 quarters · filed 2026-04-24 |
| 2023-12-31 | $546.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | $604.00M derived: sum of 2 quarters · filed 2026-04-24 | $846.00M derived: sum of 3 quarters · filed 2026-04-24 | $1.02B DEF 14A · filed 2026-04-24 |
| 2023-09-30 | $58.00M 10-Q · filed 2024-11-01 | $300.00M derived: sum of 2 quarters · filed 2024-11-01 | $477.00M 10-Q · filed 2024-11-01 | $585.00M derived: sum of 4 quarters · filed 2026-04-24 |
| 2023-06-30 | $242.00M 10-Q · filed 2024-08-07 | $419.00M 10-Q · filed 2024-08-07 | $527.00M derived: sum of 3 quarters · filed 2026-04-24 | $754.00M derived: sum of 4 quarters · filed 2026-04-24 |
| 2023-03-31 | $177.00M 10-Q · filed 2024-05-03 | $285.00M derived: sum of 2 quarters · filed 2026-04-24 | $512.00M derived: sum of 3 quarters · filed 2026-04-24 | $746.00M derived: sum of 4 quarters · filed 2026-04-24 |
| 2022-12-31 | $108.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | $335.00M derived: sum of 2 quarters · filed 2026-04-24 | $569.00M derived: sum of 3 quarters · filed 2026-04-24 | $917.00M DEF 14A · filed 2026-04-24 |
| 2022-09-30 | $227.00M 10-Q · filed 2023-11-03 | $461.00M derived: sum of 2 quarters · filed 2023-11-03 | $809.00M 10-Q · filed 2023-11-03 | $1.01B derived: sum of 4 quarters · filed 2026-04-24 |
| 2022-06-30 | $234.00M 10-Q · filed 2023-08-09 | $582.00M 10-Q · filed 2023-08-09 | $784.00M derived: sum of 3 quarters · filed 2026-04-24 | $1.11B derived: sum of 4 quarters · filed 2026-04-24 |
| 2022-03-31 | $348.00M 10-Q · filed 2023-05-05 | $550.00M derived: sum of 2 quarters · filed 2026-04-24 | $873.00M derived: sum of 3 quarters · filed 2026-04-24 | $1.30B derived: sum of 4 quarters · filed 2026-04-24 |
| 2021-12-31 | $202.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | $525.00M derived: sum of 2 quarters · filed 2026-04-24 | $952.00M derived: sum of 3 quarters · filed 2026-04-24 | $1.35B DEF 14A · filed 2026-04-24 |
| 2021-09-30 | $323.00M 10-Q · filed 2022-11-04 | $750.00M derived: sum of 2 quarters · filed 2022-11-04 | $1.15B 10-Q · filed 2022-11-04 | $1.52B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $427.00M 10-Q · filed 2022-08-05 | $826.00M 10-Q · filed 2022-08-05 | $1.19B derived: sum of 3 quarters · filed 2023-02-27 | $1.74B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $399.00M 10-Q · filed 2022-05-06 | $767.00M derived: sum of 2 quarters · filed 2023-02-27 | $1.31B derived: sum of 3 quarters · filed 2023-02-27 | $1.86B derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $368.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $915.00M derived: sum of 2 quarters · filed 2023-02-27 | $1.46B derived: sum of 3 quarters · filed 2023-02-27 | $2.16B 10-K · filed 2023-02-27 |
| 2020-09-30 | $547.00M 10-Q · filed 2021-11-12 | $1.09B derived: sum of 2 quarters · filed 2021-11-12 | $1.79B 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $542.00M 10-Q · filed 2021-08-16 | $1.25B 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $703.00M 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | $3.22B 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |